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coactivating hypoxia-inducible factor-1-dependent gene
expression
Abstract
Hypoxia-inducible factor 1 (HIF-1) is the key transcription factor regulating hypoxia-dependent gene
expression. Lack of oxygen stabilizes HIF-1, which in turn modulates the gene expression pattern to
adapt cells to the hypoxic environment. Activation of HIF-1 is also detected in most solid tumors and
supports tumor growth through the expression of target genes that are involved in processes like cell
proliferation, energy metabolism, and oxygen delivery. Poly(ADP-ribose) polymerase 1 (PARP1) is a
chromatin-associated protein, which was shown to regulate transcription. Here we report that chronic
myelogenous leukemia cells expressing small interfering RNA against PARP1, which were injected into
wild-type mice expressing PARP1, showed tumor growth with increased levels of necrosis, limited
vascularization, and reduced expression of GLUT-1. Of note, PARP1-deficient cells showed a reduced
HIF-1 transcriptional activation that was dependent on PARP1 enzymatic activity. PARP1 neither
influenced binding of HIF-1 to its hypoxic response element nor changed HIF-1alpha protein levels in
hypoxic cells. However, PARP1 formed a complex with HIF-1alpha through direct protein interaction
and coactivated HIF-1alpha-dependent gene expression. These findings provide convincing evidence
that wild-type mice expressing PARP1 cannot compensate for the loss of PARP1 in tumor cells and
strengthen the importance of the role of PARP1 as a transcriptional coactivator of HIF-1-dependent gene
expression during tumor progression.
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ABSTRACT 
HIF-1 is the key transcription factor regulating hypoxia-dependent gene expression. 
Lack of oxygen stabilizes HIF-1 that in turn modulates the gene expression pattern to adapt 
cells to the hypoxic environment. Activation of HIF-1 is also detected in most solid tumors 
and supports tumor growth through the expression of target genes which are involved in 
processes like cell proliferation, energy metabolism and oxygen delivery. Poly(ADP-
ribose)polymerase 1 (PARP1) is a chromatin-associated protein, which was shown to 
regulate transcription. Chronic myelogenous leukemia cells expressing siRNA against 
PARP1 injected into wild type mice expressing PARP1 showed tumor growth with increased 
levels of necrosis, limited vascularization and reduced expression of Glut-1. Of note, PARP1 
deficient cells showed a reduced HIF-1-transcriptional activation that was dependent on 
PARP1’s enzymatic activity. PARP1 did neither influence binding of HIF-1 to its hypoxic 
response element nor did it change HIF-1α protein levels in hypoxic cells. However, PARP1 
formed a complex with HIF-1α through direct protein interaction and co-activated HIF-1α-
dependent gene expression.  These findings provide convincing evidence that wild type mice 
expressing PARP1 cannot compensate for the loss of PARP1 in tumor cells and strengthen 
the importance of PARP1’s role as transcriptional co-activator of HIF-1-dependent gene 
expression during tumor progression.  
 
 
 
 
Running title: PARP1 co-activates HIF-1-dependent gene expression 
Keywords: PARP1; HIF; gene expression; cell survival; cancer
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INTRODUCTION 
In solid tumors rapid cell proliferation is associated with areas of hypoxia. Intra-
tumoral hypoxia induces neo-angiogenesis, which is an essential switch from tumorigenesis 
to tumor progression (1). Oxygen limitation regulates vascularization, glucose metabolism, 
cell survival and tumor spread. The hypoxic response critically depends on the transcription 
factor HIF-1 (2). HIF-1α was found overexpressed in more than 70% of human cancers and 
their metastases (3). The effect of HIF-1 on tumor growth is complex and involves the 
activation of several adaptive pathways and results in the induction of target genes (4). In 
solid tumors immunohistochemistry often shows larger fronts of HIF nuclear expression 
delineating areas of necrosis (5). Induction of HIF is therefore believed to be supportive, if 
not causative, in cancer (6-8). In tumor-xenograft and orthotopic mouse models, 
manipulation of the levels of either HIF-1α or HIF-2α has demonstrated a causal link 
between HIF expression and tumor progression (4). HIF signaling has emerged as an 
important hypoxia-driven response allowing tumor cells to survive, expand and invade. As a 
result, tumor hypoxia or HIF expression is strongly associated with a diminished therapeutic 
response and malignant progression (9). 
HIF Induction is a multi-step process, which is tightly regulated in vivo (10, 11). HIF-
1 is composed of two polypeptides: HIF-1α and HIF-1ß (12). Two additional HIF-α 
members, the closely related HIF-2α (13) and more distantly related HIF-3α (14), were 
identified recently. HIF-1 activity is regulated at the posttranscriptional level by protein 
degradation of HIF-1α subunits after oxygen-dependent hydroxylation of specific proline 
residues (15). During hypoxia, the prolyl hydroxylases are inactive and HIF-1α is not 
complexed with the ubiquitin E3 ligase complex containing VHL, thereby allowing for the 
formation of active HIF-1 complexes (2, 5, 12). Transactivation involves dimerization of the 
two HIF-1 subunits, which bind to an enhancer element called hypoxia-response element 
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(HRE) in target genes. Among the most studied promoters regarding the recruitment of HIF-1 
are those of the EPO, GLUT1 and CA9 (CAIX) genes (16-18). The presence of HRE sites is 
necessary, but not sufficient to direct gene expression in response to hypoxia, suggesting that 
HIF-1 must interact with other transcription factors or cofactors bound around these sites 
(19). The assembly of a higher order HIF-1 transcription complex is an important stage in 
HIF-1-dependent transcription, involving multiple co-activator/co-factor-HIF-1-DNA 
interactions. Two key co-activators of HIF-1 are the histone-acetyltransferases p300 and its 
homolog, the CREB-binding protein (CBP), which can directly associate with the carboxy-
terminal transactivation domain (C-TAD) of HIF-1α. HIF-1α also interacts with other co-
activators such as SRC-1 and TIF1 (20). 
Poly(ADP-ribose) polymerase-1 (PARP1) is a nuclear chromatin associated protein 
and belongs to a large family of enzymes that can synthesize polymers of ADP-ribose units 
by using β-nicotinamide adenine dinucleotide (NAD+) as substrate (21). Several studies 
showed that PARP1(-/-) mice were protected against myocardial infarction, streptozotocin-
induced diabetes, lipopolysaccharide (LPS)-induced septic shock, zymosan-induced vascular 
failure, a non-septic model of multiple organ dysfunction as well as collagen-induced arthritis 
(21). We recently presented evidence that PARP1 can act as a co-activator of NF-κB in vivo 
(22).  
In a TPA-induced skin cancer model, PARP1 was suggested to be important for 
tumor induction (23). The importance and contribution of PARP1 for tumor progression in 
tumor cells is still not clear. Here we present evidence that tumors derived from chronic 
myelogenous leukemia (CML) cell line K562 lacking PARP1 but grown in wild type mice 
expressing PARP1 show a significant increase in necrotic areas, reduced vascularization and 
reduced expression of GLUT-1, a HIF-1-dependent gene. HIF-1-dependent gene expression 
was also reduced in siPARP1 expressing K562 or primary PARP1(-/-) mouse lung fibroblasts 
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(MLF). PARP1 interacted directly with HIF-1α providing convincing evidence that PARP1 
acts mechanically as transcriptional cofactor of HIF-1α-transcriptional activation. 
Interestingly, HIF-1-dependent gene expression was dependent on the enzymatic activity of 
PARP1. Taken together, our results show that PARP1 and its enzymatic activity are 
important for tumor progression, possibly leading to new therapeutic approaches for the 
treatment of human tumors. 
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RESULTS 
 
Down-regulation of PARP1 induces areas of necrosis in tumors 
To test the role of PARP1 in tumor progression, we stably transduced cell line K562, 
with a construct expressing siRNA against PARP1 (siPARP1) or the corresponding mock 
control using a scrambled sequence (siMock). Down-regulation of PARP1 was analyzed by 
immunoblot of cell lysates (see Supplementary Figure 1A). The established siMock and 
siPARP1 cells were subcutaneously injected in both flanks of athymic nude mice. First signs 
of tumor formation appeared as early as 1 week post-injection for both cell groups. The 
formation of tumors was obvious 2 weeks after implantation. Tumor growth was similar in 
both mouse groups, irrespective of PARP1 down-regulation (Figure 1A). To confirm that 
PARP1 was still down-regulated in these tumors, we stained the sections with anti-PARP1 
antibody (Figure 1B). While siMock tumors were positive for PARP1, no signal was visible 
in siPARP1 tumors. Histological evaluation of tumors from siPARP1 cells showed larger 
areas of necrosis (areas with no nuclear-blue staining) compared to their controls (Figure 1C). 
Quantification of necrotic areas revealed that the incidence (number of lesions) and size of 
lesions was increased in tumors expression siPARP1 (12-22 lesions per tumor in siPARP1 
tumors versus 2-9 lesions in siMock tumors (Figure 1D and data not shown)). The areas of 
cell death with histological necrotic features were further analyzed by detection of glucose 
transporter GLUT-1, which is known to be upregulated in the hypoxic areas of tumors (24). 
While siMock tumors showed almost homogenous presence of GLUT-1, large areas without 
GLUT-1 staining were observed in siPARP1 tumors (Figure 1E). Immunohistochemical 
analysis with the endothelial marker CD31 revealed a significantly decreased blood vessel 
density in the siPARP1 tumors (Figure 2). The reduced vascularization corresponded well 
with the increased number of necrotic areas observed in siPARP1 tumors, indicating limited 
blood supply. Repeated experiments with mouse colon carcinoma cell line MC38 injected in 
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a syngeneic mouse model (C57BL/J6) provided the same pattern of enhanced necrosis in the 
absence of PARP1 (data not shown). These data indicate that the constitutive down-
regulation of PARP1 by siRNA did not affect tumor growth within the limits allowed by 
animal protocol, but caused larger areas of cell death, which in turn could affect tumor 
progression. Together with the reduced levels of GLUT-1 in siPARP1 tumors, those results 
suggested the involvement of PARP1 in HIF-dependent gene expression.  
 
HIF-dependent gene expression is impaired in siPARP1 expressing K562 cells  
To test whether PARP1 influences HIF-dependent gene expression, siMock and 
siPARP1 expressing K562 cells were treated with CPX (25), a hypoxiamimetic drug as 
indicated and the expression of HIF-dependent genes was assessed by transient transfection 
of a reporter gene under the control of HRE (Figure 3A). The experiments revealed that 
CPX-induced expression levels of the reporter gene were dependent on HIF and severely 
reduced in siPARP1 expressing K562 cells. Transfection of siPARP1 expressing K562 cells 
with a non-degradable PARP1 restored the observed HIF-1-dependent gene expression 
(Figure 3A), confirming that PARP1 is required for HIF-1-dependent gene expression. 
 
HIF-dependent gene expression is impaired in primary PARP1(-/-) MLF 
To further investigate the contribution of PARP1 in HIF-dependent gene expression, 
primary PARP1(+/+) and PARP1(–/–) mouse lung fibroblasts (MLF) were exposed to 
different concentrations of CPX or hypoxia as indicated, and the expression of HIF-
dependent genes was assessed by reporter gene analysis as described above (Figure 3B and 
C). CPX-induced expression of the reporter gene was again severely reduced in PARP1(–/–) 
cells when compared to wild type MLF (Figure 3B). The experiments under hypoxic 
conditions (1% O2) confirmed that PARP1 is important for HIF-1-dependent gene expression 
(Figure 3C).  
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The enzymatic activity of PARP1 is required for full HIF-dependent transcription 
To explore whether the enzymatic activity was important for HIF-dependent gene expression, 
cells were treated with the PARP inhibitor DAM-TIQ-A. Efficacy of the inhibitor was tested 
in K562 cells treated with H2O2. DAM-TIQ-A was shown to efficiently suppress the H2O2-
induced formation of poly(ADP-ribose) (Supplementary Figure 1B). siMock and siPARP1 
expressing K562 cells were then treated with DAM-TIQ-A and subsequently incubated under 
hypoxic conditions (1% O2). RNA levels of HIF-1 target gene carbonic anhydrase IX (CAIX) 
were measured by quantitative real-time PCR (Figure 3D). Inhibition of PARP1 in siMock 
cells also resulted in a reduction comparable to the level obtained by knock-down of PARP1. 
Treatment of siPARP1 expressing cells with inhibitor did not further reduce CAIX 
expression levels.  
 
Normal HIF-1 signaling in PARP1-deficient cells 
To investigate the molecular mechanism of PARP1 regulation of HIF-1-dependent 
gene expression, we analyzed whether the activation of the HIF-1-signaling pathway is 
overall affected in PARP1-deficient cells upon stimulation with CPX or hypoxia. 
Immunoblot analysis of nuclear extracts from siMock and siPARP1 expressing K562 
revealed that HIF-1α was induced to equal levels after stimulation with CPX (Figure 4A). 
Additionally, these experiments showed that there is equivalent nuclear stabilization of HIF-
1α in the tested cells. Repeated experiment with PARP1(+/+) and (-/-) MLF provided the 
same conclusions (data not shown). DNA binding activity of HIF-1 on naked templates was 
tested by EMSA studies with MLF extracts and DNA oligonucleotides corresponding to the 
HRE sites of the erythropoietin EPO promoter. PARP1 deficiency did not influence HIF-1 
 9 
binding to the template (Figure 4B). Addition of an anti-HIF-1 antibody induced a supershift, 
confirming that HIF-1 was indeed present in the observed complex (Figure 4C). 
 
PARP1 forms a complex with HIF-1 and binds directly to HIF-1 in vitro 
HIF-1 and p300/CBP were shown to form a ternary complex and to function synergistically 
to enhance the activity of nuclear receptors (26). Thus, PARP1 might also synergistically co-
activate HIF-1-mediated transactivation. In order to directly test whether PARP1 physically 
interacts with HIF-1, we immunoprecipitated PARP1 from HeLa whole cell extracts after 
stimulation with CPX and tested for the presence of HIF-1α by immunoblot analysis. HIF-1α 
formed a complex with PARP1 (Figure 5A), which was not mediated by DNA since the 
presence of ethidium bromide did not affect complex formation (data not shown). To further 
confirm a direct protein-protein interaction we bound recombinant purified full-length GST-
PARP1 to glutathione beads followed by incubation with in vitro-translated HIF-1α subunit 
and bound proteins were resolved by SDS-PAGE. PARP1 bound directly to the HIF-
1α subunit (Figure 5B). Similar binding was observed for HIF-2α but not to HIF-3α,  HIF-1β 
or HIF-2β subunits (Supplementary Figure 1C and data not shown).  
 
Expression of PARP1 increases HIF-1α-dependent transactivation in PARP1 (-/-) cells.  
To further investigate the functional relevance of the PARP1-HIF-1α interaction, 
primary PARP1(+/+) and (–/–) mouse lung fibroblasts (MLF) were transfected with an 
expression plasmid for HIF-1α, and the expression of HIF-1α-dependent genes was assessed 
by reporter gene analysis as described above (Figure 3). Transcriptional activation by HIF-1α 
expression was again severely reduced in PARP1(–/–) cells when compared to wild type 
MLF (Figure 5C). The same experiment using a plasmid with a mutated promoter confirmed 
that the observed gene expression is indeed HIF-1α specific. Assuming that the reduced 
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luciferase levels in the PARP1(-/-) MLF (Figure 3 and 5C) are indeed due to the absence of 
PARP1, one expects that complementation of PARP1(-/-) cells with the wild type PARP1 
gene restores HIF-1α-dependent gene expression. HIF-dependent reporter plasmids (wild 
type and mutant) were therefore cotransfected in PARP1(-/-) MLFs with expression vectors 
for HIF-1α and PARP1. Overexpression of PARP1 or HIF-1α alone could not or modestly 
activate HIF-dependent gene expression, however, coexpression of HIF-1α with PARP1 
synergistically activated HIF-1α-dependent transcriptional activation (Figure 5D). In the 
same set of experiments we did not observe transcriptional co-activation of HIF-2α by 
PARP1, suggesting that HIF-2α might be regulated differentially by PARP1. The regained 
ability of the PARP1(-/-) MLF to activate genes in a HIF-1α-dependent manner upon 
reintroduction of PARP1 provides convincing functional evidence that PARP1 acts a 
classical transcriptional co-activator of HIF-1-depedent gene expression. 
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DISCUSSION 
HIF-1 regulated genes have been implicated in promotion of tumor progression and 
metastasis by enhancing angiogenesis, cell proliferation and the resistance to apoptotic cell 
death (27). In this study we find that PARP1 is a regulator of HIF-1-dependent xenograft 
tumor progression. Mechanistically, we identified PARP1 as a transcriptional co-activator of 
HIF-1-induced gene expression and we determined a novel process of HIF-1 regulation under 
hypoxia that acts through PARP1 by regulating target gene expression of critical HIF-1 genes 
such as GLUT-1, CAIX, EPO and VEGF. 
The knockout strategy has revealed an important role of PARP1 in cell death after 
myocardial or brain ischemia-reperfusion injury (28, 29). Significant protection against 
oxidant-induced tissue damage can also be achieved with pharmacological PARP1 inhibitors 
(30). The most obvious explanation for this observation is that upon reperfusion, oxygen-
derived free radicals, NO and peroxynitrite induce DNA breaks, that in turn overactivate 
PARP1 (31). This excessive activation leads to intracellular NAD and ATP depletion 
resulting in mitochondrial free radical generation and necrosis (32, 33). Whether these 
observed effects are due to anoxia or reduced nutritional supply or both (i.g. ischemia) is 
currently not clear. In our tumor model, we found PARP1 to promote cell survival rather than 
death. The observed increase in necrotic areas in tumors grown from PARP1-deficient cells 
was also accompanied by a decrease in vascularization of tumors. These findings are in 
agreement with earlier observation that inhibition of PARP1 decreases angiogenesis in an in 
vitro model (34). We therefore propose that insufficient oxygen and nutrient supply due to 
impaired HIF-1 activation is the cause for the increased necrosis during tumor progression, 
independent of radical oxygen species formation. Experiments by Tong et al. provided 
evidence that in a p53-/- background PARP1 is important as cofactor for suppression of 
tumorigenesis in certain tissues (35). Conde reported that injection of ras-transformed parp1-
/-p53-/- cells failed to generate any visible tumor (36). We did not observe an influence of 
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PARP1 protein on tumor latency and cell proliferation using K562 or MC38 cells (data not 
shown). This could be due to the fact that both cell lines are expressing functional p53. 
Furthermore, our results indicate that in a p53 proficient background, PARP1 acts as 
promoter of tumor survival as demonstrated by the increase of necrosis in tumors formed by 
siPARP1-expressing K562 and MC38 cells. Obviously the tissue expressing PARP1 around 
the tumors was not able to overcome the lack of PARP1 in the tumor cells. 
Our gene expression studies suggest a transcriptional co-activator role for PARP1 in 
HIF-1-dependent gene expression since in the absence of PARP1, impaired expression of 
HIF-1-dependent genes was found when mouse fibroblasts and K562 cells were exposed to 
CPX or hypoxia. Interestingly, the protein levels of HIF-1 were not reduced in treated cells, 
indicating that the signaling pathway and turn over rate of HIF-1 per se were not affected. 
Moreover, the DNA binding activity of HIF-1 assayed in vitro on naked non-chromatinized 
templates was not impaired in nuclear extracts from PARP1 (-/-) fibroblasts, suggesting that 
HIF-1 does not require PARP1 for binding to its HRE.  
Complementation experiments of PARP1 (-/-) cells with a PARP-1 expression 
plasmid confirmed that PARP-1 is required when HIF-dependent gene expression is activated 
by HIF-1α overexpression. We detected endogenous PARP1 in a complex with HIF-1. 
Moreover, PARP1 directly bound to the HIF-1α subunit in vitro. Together these observations 
implicate that PARP1 is playing a critical and central role downstream of the HIF signaling 
pathway and strengthens the involvement of PARP1 as transcriptional co-activator. It is of 
great interest to elucidate the relationship of PARP1 to other HIF-1-associated co-activators 
regarding their relative contribution to HIF-1-dependent gene activation, with respect to 
different promoters and stimuli. Chromatin immunoprecipitation experiments could be 
employed to study the presence of PARP1 at promoters of HIF-1-dependent genes. 
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Unfortunately such experiments are made difficult by the lack of suitable antibodies and the 
high affinity of PARP1 for DNA strand breaks in general.  
The requirement of PARP1 enzymatic activity for HIF-1-dependent transcription is 
shown by experiments including PARP inhibitors. As such, expression of CAIX was reduced 
in the presence of the PARP inhibitor DAM-TIQ-A. Thus, for at least a subset of PARP1-
dependent HIF-1 target genes, the enzymatic activity of PARP1 is necessary for full 
activation. Whether only PARP1 is poly(ADP-ribosylated) or also other factors, such as 
histones or even HIF-1α, has to be further elucidated. Two groups reported recently that lack 
of homologous recombination by BRCA1 and 2 dysfunction sensitized tumor cells to the 
inhibition of PARP enzymatic activity (37, 38). Others provided evidence that the enzymatic 
activity of PARP1 can also be induced by D-myo-inositol-1,4,5-triphosphate in a DNA 
damage independent mechanism (39). Whether the observed effect of PARP inhibitor is due 
to the PARP1’s activation induced by damaged DNA or other stimuli has to be further 
investigated. PARP inhibitors were also reported to possess free radical scavenging 
properties (40). Since hypoxia could potentially induce local oxidative stress, it is tempting to 
speculate that PARP inhibitors with anti-oxidative potency contribute indirectly and non-
specifically to decreased HIF-1 dependent transcriptional activity by reduction of free 
radicals. We can not exclude that the observed effects are due to the off-targeting activity of 
PARP inhibitors (41, 42). The residual activation of gene expression in the presence of PARP 
inhibitor might be explained by a process that is independent from PARP1. The small 
observed difference between siRNA knockdown and pharmacological inhibition on the other 
hand could be due to incomplete knockdown of PARP1 or the contribution of other PARP 
family members. 
Martin-Oliva et al. recently provided evidence that the number of DMBA and TPA 
induced skin tumors is reduced in mice treated with PARP inhibitor, suggesting that PARP1 
is important for tumor initiation. They suggested that the transcriptional activity of HIF-1 was 
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compromised by PARP inhibition or in immortalized PARP1-deficient cells upon stimulation 
with TPA or desferoxamine (DFX) (an iron chelator and activator of HIF) (23). In contrast, 
our studies provide evidence that PARP1 is important for the progression of tumors formed 
by transformed cell lines and that wild type mice expressing PARP1 cannot compensate for 
the loss of PARP1 in cancer cells. One possible explanation for the observed differences is 
the differences in examined tumor types. Furthermore our studies with primary PARP1(-/-) 
MLF and siPARP1 expressing cells under hypoxic conditions or treated with a 
hypoxiamimetic drug revealed that HIF-1-signaling (HIF-1 protein stability and DNA 
binding) per se is not affected by PARP1. 
 By integrating our data with previous findings, we propose a model by which HIF-1 
regulation under hypoxic conditions occurs additionally through PARP1 as transcriptional 
co-activator. The presence of PARP1 stimulates HIF-1-dependent gene expression and thus 
allows induction of genes involved in neoangiogenesis and cell survival. From a therapeutic 
point of view, inhibition of PARP1 enzymatic activity could be an effective target in 
conditions of tissue ischaemia, as tumors lacking PARP1 show increased necrosis upon 
ischaemic insult. Thus, well-tolerated PARP1 inhibitors that are known to inhibit PARP1 
enzymatic activity (38) could be beneficial in the treatment of HIF-1-dependent tumor 
progression. 
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MATERIALS AND METHODS 
Reagents and antibodies 
Ciclopirox olamine was purchased from Sigma and dissolved in methanol before 
diluting to final concentration in supplemented media. Radiochemicals were obtained from 
Amersham Biosciences. The anti-PARP1 antibody is described in (43) and the anti-HIF-1α 
in (44). Anti-mouse IgG was purchased from Santa Cruz Biotechnology. Anti-GLUT1 
antibody was purchased from Abcam. Anti-PAR antibody was a kind gift of Guy Poirier. 
Mice strains and experiments  
All animal procedures were performed in accordance with the regulations of the 
Cantonal Veterinary Authority of Zurich in accordance with the Swiss laws on animal 
protection. 
For the tumor growth studies athymic nude mice (HsdCpb: NMRI-Foxn1nu) were 
obtained from Harlan Laboratories, Germany. Eight weeks old females were injected 
subcutaneously with 8 x 106 K562 CML cells, which were either stably transfected with 
siRNA towards PARP1 (siPARP1 tumors) or transfected with mock siRNA (siMock tumors). 
Tumor growth was checked regularly and mice were terminated when the size of tumor was 
reaching approved limits.  
 
Histology 
Dissected tumors were macroscopically evaluated, cut in half and frozen in 
embedding medium (Tissue-Tek O.C.T Compound Sakura, USA, Inc). Paraformaldehyde 
fixed cryosections (8 µm) were blocked in 0.5% BSA and incubated with either polyclonal 
rabbit-anti-PARP1 or rabbit-anti-GLUT1 (Abcam, Inc.) antibody for 1 h at RT, respectively. 
Tumors were further incubated with Cy3 conjugated goat-anti-rabbit antibodies (Jackson 
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ImmunoResearch) followed by nuclear staining with DAPI and mounting in Prolong medium 
(Invitrogen). Formaline fixed cryosections were stained by Hematoxylin and Eosin (H&E) 
and evaluated for the presence of necrosis. The quantification of necrosis was performed on 
the whole area of each tumor in several sections. Blood vessels were stained with CD31 
antibody (Becton Dickinson). Specific binding was detected using the Vectrastain ABC Kit 
with the AEC substrate (Vector Laboratories) followed by hematoxylin counterstaining. 
Generation of siRNA cell lines 
Generation of viruses and transduction of cells were described previously (45). After several 
rounds of selection expression level of PARP1 was screened by immunoblot analysis.  
Cell culture, transient transfection and nuclear extracts 
Mouse PARP1(+/+) or PARP1(–/–) MLF cells were isolated from 129S/EV-
PARP1(+/+) and 129S/EV-PARP1(-/-) mice, both described in (46). Only cell passages 2 to 
10 were used for experiments. MLF and HeLa cell lines were grown in D-MEM Glutamax-I 
(Invitrogen) containing 4.5 g/l glucose. K562 cells were grown in RPMI (Invitrogen). All 
media were supplemented with 10% fetal calf serum (Invitrogen), 50 U/ml penicillin, 50 
µg/ml streptomycin (Sigma) and NAA (Invitrogen). Cells were grown in 5% CO2 at 37 °C in 
a humidified incubator. MLF and HeLa cells were transfected with polyethylenimine (PEI) or 
calcium-phosphate, K562 cells with DEAE-Dextran as described previously. Because of 
differences in transfection efficiencies, an expression plasmid of β-galactosidase (pph-RSV-
nt-β-gal, (47)) was co-transfected as a transfection efficiency control, and luciferase activities 
were normalized based on β-galactosidase activity. In case of K562 and MLF, normalization 
was performed with total protein amount measured by Bradford assay. Luciferase activity 
was measured as described in (48). Nuclear extracts of HeLa and K562 cells were produced 
as described by (49). 
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Quantitative real-time PCR 
Total RNA of cells was extracted using the RNA Isolation Mini Kit (Agilent) and 
following the manufacturers protocol. RNA was then reverse-transcribed using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative PCR was 
performed on a Rotor-Gene 3000 machine (Corbett Research) using TaqMan probes (Applied 
Biosystems) against two endogenous controls (ribosomal proteins P0 and S14) and against 
carbonic anhydrase IX. Quantitation was done using the Rotor-Gene software version 6.1 
(Corbett Research) and the built-in two-standard-curve method. 
Plasmids 
The reporter plasmid p5xHREwt was created by cloning one oligonucleotide 
containing a HIF-1 binding site from the VEGF promoter (5'-
AGCTTGATATCGGATCCGCATACGTGGGCTCCAACAGGTCCTCTTCCCTCCCAGT
CACTGACTAACCCT-3', binding site underlined) and two oligonucleotides containing two 
binding sites from the EPO promoter (5'-
AGCTTGGATCCGGCCCTACGTGCTGCCTCGCATGGGCCCTACGTGCTGCCTCGCA
TGGCCC-3', binding sites underlined) into the multiple cloning site of pGL3-Basic 
(Promega). For p5xHREmut the oligonucleotides were the same except for the binding sites 
which were changed to 5'-TAAAAGGG-3' and 5'-TAAAAGCT-3' respectively. Expression 
vectors CMV-HIF-1α, CMV-HIF-2α and CMV-HIF-3α used for in vitro transcription were 
constructed by PCR amplification of the ORF of I.M.A.G.E. cDNA clones #3842146, 
#6305604 and #6250259 respectively. PCR products were then ligated into pphCMV-T7-km-
3 described in (50). 
shRNA coding sequences (available upon request) were cloned into pSUPER vector 
by using BglII and HindIII cloning sites. BamHI/SalI fragment containing HI promoter 
upstream of shRNA coding sequence was subcloned into pRDI292 vector (51). The envelope 
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plasmid pMD.G and the packaging plasmid pCMV ∆R8.91 have been previously described 
(45). 
In Vitro Transcription/Translation and GST Pull-down Assays 
GST and GST-PARP1 were expressed in Escherichia coli. In vitro 
transcription/translation reactions were carried out using the TNT T7 Quick Coupled 
Transcription/Translation System (Promega) according to the manufacturer's protocol. GST 
pull-down assays were performed using bacterial extracts, glutathion-sepharose beads 
(Amersham Pharmacia Biotech) and the radiolabeled product in the presence of 80 mM NaCl 
as described in (52). 
Immunoprecipitation and Immunoblot 
For immunoprecipitation 1 mg of HeLa nuclear extracts were incubated with anti-
PARP1 serum or preimmune serum in IP buffer containing 80 mM NaCl and Protein-A -
Sepharose beads (Amersham Biosciences). Beads were then washed extensively in the 
presence of 100 mM NaCl and 0.05% Nonidet-P-40, followed by SDS-PAGE and 
immunoblot analysis according to the manufacturer's protocol (ECL; Pierce). 
EMSA 
The electrophoretic mobility shift assay was performed as described in (53). Briefly, 
the oligonucleotides 5'-GCCCTACGTGCTGCCT-3' and 5'-GCCCTAAAAGCTGCCT-3' 
were annealed to their antisense counterpart, labeled with 32P by T4 PNK and purified over 
Microspin G-25 columns (Amersham Biosciences). The radiolabeled oligonucleotides were 
then added to 10 µg of HeLa nuclear extract. After 20 min, samples were loaded and 
separated on a 4% native acrylamide gel. The gels were then dried for autoradiography. For 
competition, HeLa nuclear extracts were preincubated for 5 min with unlabeled competitor 
oligonucleotides for a final ratio of 25:1 of unlabeled over labeled oligonucleotide. For super-
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shift, nuclear extracts were preincubated for 20 min with anti-HIF-1α or with an unrelated 
anti-mouse IgG antibodies.  
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FIGURE LEGENDS 
 
Figure 1. The down-regulation of PARP1 enhances tumor cell death, but does not affect 
tumor growth.  
Chronic myeloid leukemia cell line, K562, was subcutaneously injected in athymic nude 
mice. Cells with down-regulated PARP1 gene by transduction of a siRNA against PARP1 
(siPARP1) were compared to cells transfected with a control siRNA (siMock).  
A) Tumor growth curves for siMock ( ), and siPARP1 ( ) injected mouse groups (4 mice 
and 8 implantation sites for each group). Error bars indicate S.E.M. 
B) Staining of tumor sections with anti-PARP1 antibody confirmed the sustained down-
regulation of PARP1 in tumor cells after subcutaneous growth in mice. PARP1 staining (red), 
nuclei staining, DAPI (blue) and merged image (merge) indicated presence of PARP1 in the 
nuclei of wt tumors. 
C) Representative pictures of tumors stained by H&E indicating an enhanced presence of 
necrotic tumor areas in siPARP1 tumors.  
D) Quantification of necrotic lesions. All tumors were sequentially sectioned and areas from 
3 different depths of tumor were H&E stained and evaluated. Number of necrotic lesions in 
each tumor type is presented in a group of mice (p < 0.001). 
E) Staining of tumor sections with anti-Glucose-Transporter (GLUT-1) antibody (red) and 
DAPI (blue) reveals downregulation of GLUT-1 expression in siPARP1 tumors. 
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Figure 2. Reduced vascularization of K562 tumors is associated with the down regulation of 
PARP1. 
A) Tumor vasculature was evaluated by immunohistochemical staining with CD31 antibody 
(red color). Representative pictures show a higher number of blood vessels in siMock tumor 
compared to scarcely vascularized siPARP1 tumors, bar = 100 µm. 
B) Vascular density based on CD31 staining is quantified for both tumors. The decreased 
number of blood vessels in siPARP1 tumors was found statistically significant by student’s t-
test p < 0.01. 
 
Figure 3 PARP1 is required for HIF-1-dependent gene expression. 
A) Transient reporter assay in cell lines K562 siMock, siPARP1 and siPARP1 complemented 
with wild type PARP1. Cells were transfected with either the hypoxia reporter (Epo) or the 
mutated control (mut) and treated with the 15 CPX µM for 10 hours. Cells were harvested 
and hypoxia-dependent gene expression was determined. The depicted fold increase is 
calculated as the ratio of normalized luciferase activity of the Epo reporter over the mut 
reporter. Error bars indicate range of two replicates. 
B) PARP1(+/+) and (-/-) mouse lung fibroblasts were transfected with either the hypoxia 
reporter (Epo) or the mutated control (mut) and treated with the indicated amount of CPX for 
12 hours. Cells were harvested and hypoxia-dependent gene expression was determined. The 
depicted fold increase is determined by normalization of the relative luciferase activity of the 
reporter plasmids to that of an internal control (RSV-βGal). The ratios for untreated mutant 
reporter in both cell lines were arbitrarily set to 1. Error bars indicate range of two replicates. 
C) Cells were prepared as in panel B but kept in either normoxic (21%) or hypoxic (1%) 
conditions for 9 hours after transfection. The depicted fold increase is calculated as the ratio 
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of normalized luciferase activity of the Epo reporter over the mut reporter. Error bars indicate 
S.D. of three replicates. 
D) Quantitative RT-PCR analysis of CAIX expression. siMock and siPARP1 expressing 
K562 were treated with DAM-TIQ-A as indicated and incubated in normoxic (21% O2) or 
hypoxic (1% O2)conditions. Induction is defined as the ratio of hypoxic over normoxic CAIX 
levels. The induction of untreated siMock cells was arbitrarily set to 100%. Error bars 
indicate S.D. of four replicates. 
 
Figure 4 HIF-1 stabilization and DNA-binding activity is not affected in PARP1 (-/-) cells. 
A) K562 siMock and siPARP1 cell lines were treated with 15 µM CPX for 14 hours. Nuclear 
proteins were then extracted and resolved by SDS-PAGE followed by immunoblot analysis 
using anti-PARP1 and anti-HIF-1α antibodies. Anti-tubulin was used as a loading control. 
B) Autoradiographs of electrophoretic mobility shift assay for with 32P-labeled 
oligonucleotides containing a HIF-1 binding site. Nuclear extracts of PARP1(+/+) and (-/-) 
mouse lung fibroblasts  treated with 10 µM CPX for 6 hours were used in the assay. 
Competition for binding was performed with unlabeled wild type and binding mutant 
oligonucleotides.  
C) Confirmation of HIF-1 binding was effected by adding anti-HIF-1 (HIF) or control IgG 
(c) antibodies for a super-shift.  
 
Figure 5 PARP1 directly interacts with HIF-1α and synergistically activates HIF-1α -
dependent gene expression. 
A) Immunoprecipitation of HIF-1α with anti-PARP1 antibody serum (α-P1) and preimmune 
serum (pre) as a control. Total extracts of HeLa cells treated with 15 µM CPX of 16 hours 
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were used. Input lane (inp) was loaded with 10% the amount of extract used for the 
immunoprecipitation. The size of protein marker bands (M) are indicated in kD. 
B) Autoradiography of in-vitro translated HIF-1α pulled down with GST-PARP1 (P1) or 
GST alone (GST). Input lane (inp) was loaded with 1% the amount of translation product 
used for the pull-down. 
C) and D) PARP1(-/-) mouse lung fibroblasts were transfected for 24 hours by PEI with 
either the hypoxia reporter (Epo) or the mutated control (mut) together with PARP1 or HIF-
1α (as indicated). Cells were harvested and hypoxia-dependent gene expression was 
determined. The depicted fold increase is determined by normalization of the relative 
luciferase activity of the reporter plasmids to the protein concentration of each sample. The 
ratios for untreated mutant reporter in both cell lines were arbitrarily set to 1. Error bars 
indicate S.D. of three replicates. 
 
Supplementary Figure 1 
A) Immunoblot analysis of K562 whole cell extracts showing efficiency of siRNA knock-
down of PARP1 in those cells. 
B) Immunostaining of K562 cells with an antibody against poly(ADP-ribose) (α-PAR). PAR 
formation was induced by treating the cells with H2O2 in the presence of either DMSO or the 
PARP1 inhibitor DAM-TIQ-A.  
C) Autoradiography of in-vitro translated HIF-2α and HIF-3α pulled down with GST-
PARP1 (P1) or GST alone (GST). Input lane (inp) was loaded with 1% the amount of 
translation product used for the pull-down. 
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